JP2017529324A5 - - Google Patents

Download PDF

Info

Publication number
JP2017529324A5
JP2017529324A5 JP2017506693A JP2017506693A JP2017529324A5 JP 2017529324 A5 JP2017529324 A5 JP 2017529324A5 JP 2017506693 A JP2017506693 A JP 2017506693A JP 2017506693 A JP2017506693 A JP 2017506693A JP 2017529324 A5 JP2017529324 A5 JP 2017529324A5
Authority
JP
Japan
Prior art keywords
seq
fragment
antibody
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017506693A
Other languages
English (en)
Japanese (ja)
Other versions
JP6649358B2 (ja
JP2017529324A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/055986 external-priority patent/WO2016020880A2/en
Publication of JP2017529324A publication Critical patent/JP2017529324A/ja
Publication of JP2017529324A5 publication Critical patent/JP2017529324A5/ja
Application granted granted Critical
Publication of JP6649358B2 publication Critical patent/JP6649358B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017506693A 2014-08-07 2015-08-06 アンジオポエチン様4抗体および使用法 Active JP6649358B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462034409P 2014-08-07 2014-08-07
US62/034,409 2014-08-07
PCT/IB2015/055986 WO2016020880A2 (en) 2014-08-07 2015-08-06 Angiopoietin-like 4 antibodies and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020004261A Division JP2020075929A (ja) 2014-08-07 2020-01-15 アンジオポエチン様4抗体および使用法

Publications (3)

Publication Number Publication Date
JP2017529324A JP2017529324A (ja) 2017-10-05
JP2017529324A5 true JP2017529324A5 (show.php) 2018-09-06
JP6649358B2 JP6649358B2 (ja) 2020-02-19

Family

ID=53836146

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017506693A Active JP6649358B2 (ja) 2014-08-07 2015-08-06 アンジオポエチン様4抗体および使用法
JP2020004261A Pending JP2020075929A (ja) 2014-08-07 2020-01-15 アンジオポエチン様4抗体および使用法
JP2022007104A Active JP7397104B2 (ja) 2014-08-07 2022-01-20 アンジオポエチン様4抗体および使用法
JP2023202489A Active JP7695330B2 (ja) 2014-08-07 2023-11-30 アンジオポエチン様4抗体および使用法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020004261A Pending JP2020075929A (ja) 2014-08-07 2020-01-15 アンジオポエチン様4抗体および使用法
JP2022007104A Active JP7397104B2 (ja) 2014-08-07 2022-01-20 アンジオポエチン様4抗体および使用法
JP2023202489A Active JP7695330B2 (ja) 2014-08-07 2023-11-30 アンジオポエチン様4抗体および使用法

Country Status (31)

Country Link
US (5) US9771417B2 (show.php)
EP (2) EP4122957A1 (show.php)
JP (4) JP6649358B2 (show.php)
KR (2) KR20240056627A (show.php)
CN (1) CN107148428B (show.php)
AP (1) AP2017009721A0 (show.php)
AR (1) AR101486A1 (show.php)
AU (1) AU2015300685B2 (show.php)
BR (1) BR112017002173B1 (show.php)
CL (1) CL2017000212A1 (show.php)
CO (1) CO2017001087A2 (show.php)
CR (1) CR20170040A (show.php)
CU (1) CU24453B1 (show.php)
DK (1) DK3177642T3 (show.php)
EA (1) EA201790336A1 (show.php)
EC (1) ECSP17013904A (show.php)
ES (1) ES2906216T3 (show.php)
IL (1) IL250289B2 (show.php)
JO (1) JO3565B1 (show.php)
MA (1) MA40512A (show.php)
MX (2) MX390418B (show.php)
NZ (1) NZ728425A (show.php)
PE (1) PE20170287A1 (show.php)
PH (1) PH12017500156A1 (show.php)
PL (1) PL3177642T3 (show.php)
PT (1) PT3177642T (show.php)
SG (2) SG10201805646WA (show.php)
TN (1) TN2017000019A1 (show.php)
TW (1) TWI675043B (show.php)
UY (1) UY36262A (show.php)
WO (1) WO2016020880A2 (show.php)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613977A (en) * 2014-08-07 2016-04-16 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EA201790336A1 (ru) 2014-08-07 2017-06-30 Новартис Аг Антитела к ангиопоэтинподобному белку 4 и способы применения
GB2569144B (en) * 2017-12-06 2021-06-16 Proimmune Ltd Method for screening the activity of mutated expressed polypeptides
US11787857B2 (en) * 2018-02-02 2023-10-17 Bio-Techne Corporation Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using
KR20210143858A (ko) * 2019-03-26 2021-11-29 얀센 파마슈티카 엔.브이. 피로글루타메이트 아밀로이드-β에 대한 항체 및 이의 용도
CN119053620A (zh) * 2022-03-16 2024-11-29 Inserm(法国国家健康医学研究院) 治疗传染病的新方法
PE20250005A1 (es) * 2022-05-02 2025-01-07 Novo Nordisk As Nuevos anticuerpos anti-angptl3 adecuados para composiciones de concentracion alta y administracion subcutanea
WO2025166073A1 (en) * 2024-01-31 2025-08-07 Alector Llc Compositions comprising anti-sortilin antibodies and uses thereof

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
WO1988009344A1 (en) 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0732402A3 (en) 1990-12-14 1997-05-21 Cell Genesys Inc Chimeric chains for transduction of receptor-linked signaling pathways
DK1024191T3 (da) 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
US5766886A (en) 1991-12-13 1998-06-16 Xoma Corporation Modified antibody variable domains
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
EP1498427B1 (en) 1992-08-21 2009-12-16 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
AU1397895A (en) 1993-12-22 1995-07-10 Temple University - Of The Commonwealth System Of Higher Education Peptide analogs of the activated platelet binding site on factor xi
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
AU3382595A (en) 1994-07-29 1996-03-04 Smithkline Beecham Corporation Novel compounds
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
AU736707B2 (en) 1997-06-11 2001-08-02 Anaphore, Inc. Trimerising module
EP2380906A2 (en) 1997-06-12 2011-10-26 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
PL220113B1 (pl) 1999-01-15 2015-08-31 Genentech Inc Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
US7001766B2 (en) 1999-07-20 2006-02-21 Curagen Corporation Nucleic acid sequences encoding human angiopoietin-like polypeptides
KR20020047132A (ko) 1999-08-24 2002-06-21 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
LT2857516T (lt) 2000-04-11 2017-09-11 Genentech, Inc. Multivalentiniai antikūnai ir jų panaudojimas
JP2003530847A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US7041870B2 (en) 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
CA2442685A1 (en) 2001-04-04 2002-10-17 Edith Bonnelye Estrogen receptor-related receptor alpha (err.alpha.) and cartilage formation
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
EP1421203A4 (en) 2001-05-17 2005-06-01 Diversa Corp NEW ANTIGEN-BINDING MOLECULES FOR THERAPEUTIC, DIAGNOSTIC, PROPHYLACTIC, ENZYMATIC, INDUSTRIAL AND AGRICULTURAL APPLICATIONS AND METHOD FOR THE PRODUCTION AND SCREENING THEREOF
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
US7217794B2 (en) 2003-04-02 2007-05-15 Daiamed, Inc. Compounds and methods for treatment of thrombosis
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
JP2007501844A (ja) 2003-08-08 2007-02-01 トランス テック ファーマ,インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
WO2005069970A2 (en) 2004-01-20 2005-08-04 Kalobios, Inc. Antibody specificity transfer using minimal essential binding determinants
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
LT1781698T (lt) 2004-07-20 2016-09-26 Genentech, Inc. Į angiopoetiną panašaus baltymo 4 kompozicijos ir panaudojimo būdai
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
DK1771474T3 (da) 2004-07-20 2010-05-31 Genentech Inc Inhibitorer af angiopoitin-like 4 protein, kombinationer og anvendelser deraf
EP1773771A2 (en) 2004-07-23 2007-04-18 Daiamed, Inc. Compounds and methods for treatment of thrombosis
KR101387781B1 (ko) 2005-01-07 2014-04-21 렉시컨 파마슈티컬스 인코퍼레이티드 앤지오포이에틴-유사 단백질 4 (angptl4) 에 대한단일클론 항체
JP5236293B2 (ja) 2005-01-13 2013-07-17 ブリストル−マイヤーズ スクイブ カンパニー Xia因子阻害剤としての置換ビアリール化合物
CA2648522A1 (en) 2005-04-04 2006-10-12 Daiamed, Inc. Substituted azetidinones
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
NZ597168A (en) 2005-08-19 2013-07-26 Abbott Lab Dual variable domain immunoglobin and uses thereof
WO2007070826A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
AU2007227251A1 (en) * 2006-03-20 2007-09-27 Amgen Fremont, Inc. Antibodies directed to angiopoietin-like protein 4 and uses thereof
DK3002298T3 (da) 2007-11-21 2019-10-28 Univ Oregon Health & Science Anti-faktor xi monoklonale antistoffer og fremgangsmåder til anvendelse deraf
US8168586B1 (en) 2007-11-21 2012-05-01 Celera Corporation Cancer targets and uses thereof
EP2265601B1 (en) 2008-03-13 2012-02-01 Bristol-Myers Squibb Company Pyridazine derivatives as factor xia inhibitors
HUE041556T2 (hu) 2008-06-19 2019-05-28 Prothix Bv XI-es faktor elleni ellenanyagok alkalmazása vérrögképzõdés megelõzésére vagy kezelésére
PL2379084T3 (pl) 2008-10-15 2018-04-30 Ionis Pharmaceuticals, Inc. Modulowanie ekspresji czynnika XI
JP5823871B2 (ja) 2008-12-10 2015-11-25 アブリンクス エン.ヴェー. 血管新生に関連した疾患及び障害の治療のための、アンジオポイエチン/Tieシステムに指向性を有するアミノ酸配列及びこれを含むポリペプチド
US20120207770A1 (en) 2009-10-14 2012-08-16 Nanyang Technological University Antiproliferative agent
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
US20120201746A1 (en) 2010-12-22 2012-08-09 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
CN102692500B (zh) * 2011-03-21 2015-06-10 上海市肿瘤研究所 Angptl4作为血清学检测肝癌转移的标志物及其应用
SG10201607346XA (en) * 2011-08-08 2016-10-28 Univ Nanyang Tech Angiopoietin-like 4 and its use in modulating cell leakiness
EP2836232A4 (en) 2012-04-13 2016-03-16 Univ Johns Hopkins TREATMENT OF ISCHEMIC RETINOPATHY
SG10201609322QA (en) 2012-05-10 2017-01-27 Bayer Pharma AG Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
SG10201701165TA (en) 2012-08-14 2017-03-30 Univ Nanyang Tech Angiopoietin-like 4 antibody and a method of its use in cancer treatment
EA201790336A1 (ru) 2014-08-07 2017-06-30 Новартис Аг Антитела к ангиопоэтинподобному белку 4 и способы применения
TW201613977A (en) 2014-08-07 2016-04-16 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use

Similar Documents

Publication Publication Date Title
JP2017529324A5 (show.php)
HRP20201975T1 (hr) Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba
RU2017102514A (ru) Гуманизированные анти-тау-антитела
JP2015514110A5 (show.php)
JP2013198490A5 (show.php)
JP2011509245A5 (show.php)
JP2018512379A5 (show.php)
JP2014205674A5 (show.php)
JP2015504421A5 (show.php)
JP2012525829A5 (show.php)
JP2017535257A5 (show.php)
JP2016530223A5 (show.php)
JP2015503909A5 (show.php)
RU2020124153A (ru) Гуманизированные антитела к cd19 человека и способы их применения
JP2014519334A5 (show.php)
JP2009225799A5 (show.php)
RU2016137110A (ru) Антитела к компоненту комплемента с5
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
RU2016100892A (ru) Антитела против tweakr и их применение
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
IL250289B2 (en) Antibodies against angiopoietin-like 4 and methods of use
JP2014511179A5 (show.php)
JP2018510617A5 (show.php)
JP2011046732A5 (show.php)
HRP20181087T1 (hr) Pripravak i postupak dijagnostike i liječenja bolesti povezanih s degeneracijom neurita